Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
2
29%
Ph phase_4
2
29%
Ph phase_3
3
43%

Phase Distribution

2

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 3Large-scale testing
3(42.9%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(4)
Completed(3)

Detailed Status

Not yet recruiting4
Completed3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (28.6%)
Phase 33 (42.9%)
Phase 42 (28.6%)

Trials by Status

completed343%
not_yet_recruiting457%

Recent Activity

0 active trials
Showing 5 of 7
not_yet_recruitingphase_4

GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

NCT07251556
not_yet_recruitingphase_4

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

NCT07073053
not_yet_recruitingphase_3

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

NCT07030621
not_yet_recruitingphase_3

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

NCT06788626
completedphase_3

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

NCT03061214
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT07251556Phase 4

GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis

Not Yet Recruiting
NCT07073053Phase 4

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

Not Yet Recruiting
NCT07030621Phase 3

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Not Yet Recruiting
NCT06788626Phase 3

Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment

Not Yet Recruiting
NCT03061214Phase 3

Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)

Completed
NCT03288740Phase 1

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Completed
NCT03611322Phase 1

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7